Short Interest in Indivior PLC (NASDAQ:INDV) Rises By 17.4%

Indivior PLC (NASDAQ:INDV) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,420,000 shares, a growth of 17.4% from the January 15th total of 1,210,000 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 1,200,000 shares, the short-interest ratio is currently 1.2 days.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on INDV shares. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $16.00 target price (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th.

Institutional Trading of Indivior

Large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Indivior during the 4th quarter worth about $56,000. Stifel Financial Corp bought a new stake in shares of Indivior during the 3rd quarter worth about $100,000. Melqart Asset Management UK Ltd bought a new stake in Indivior during the 3rd quarter valued at approximately $132,000. Rathbones Group PLC boosted its stake in Indivior by 11.6% during the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock valued at $183,000 after purchasing an additional 1,483 shares during the period. Finally, Jane Street Group LLC bought a new stake in Indivior during the 3rd quarter valued at approximately $180,000. Institutional investors own 60.33% of the company’s stock.

Indivior Trading Down 2.5 %

NASDAQ INDV traded down $0.25 on Friday, reaching $9.83. The stock had a trading volume of 731,930 shares, compared to its average volume of 1,095,976. The business has a 50 day moving average price of $11.66 and a 200 day moving average price of $10.99. Indivior has a 1 year low of $7.33 and a 1 year high of $23.22. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -245.69 and a beta of 0.73.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.